These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

396 related articles for article (PubMed ID: 25434634)

  • 81. Multicystic and well-differentiated papillary peritoneal mesothelioma treated by surgical cytoreduction and hyperthermic intra-peritoneal chemotherapy (HIPEC).
    Baratti D; Kusamura S; Nonaka D; Oliva GD; Laterza B; Deraco M
    Ann Surg Oncol; 2007 Oct; 14(10):2790-7. PubMed ID: 17661150
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Current status and future directions of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the treatment of ovarian cancer.
    Helm CW
    Surg Oncol Clin N Am; 2012 Oct; 21(4):645-63. PubMed ID: 23021722
    [TBL] [Abstract][Full Text] [Related]  

  • 83. HIPEC in patients with primary advanced ovarian cancer: Is there a role? A systematic review of short- and long-term outcomes.
    Kireeva GS; Gafton GI; Guseynov KD; Senchik KY; Belyaeva OA; Bespalov VG; Panchenko AV; Maydin MA; Belyaev AM
    Surg Oncol; 2018 Jun; 27(2):251-258. PubMed ID: 29937179
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Intra-abdominal temperature distribution during consolidation hyperthermic intraperitoneal chemotherapy with carboplatin in the treatment of advanced stage ovarian carcinoma.
    Rettenmaier MA; Mendivil AA; Gray CM; Chapman AP; Stone MK; Tinnerman EJ; Goldstein BH
    Int J Hyperthermia; 2015 Jun; 31(4):396-402. PubMed ID: 25707816
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for treatment of ovarian cancer.
    Polom K; Roviello G; Generali D; Marano L; Petrioli R; Marsili S; Caputo E; Marrelli D; Roviello F
    Int J Hyperthermia; 2016 May; 32(3):298-310. PubMed ID: 26984715
    [TBL] [Abstract][Full Text] [Related]  

  • 86. 8-year follow-up of randomized trial: cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy in patients with peritoneal carcinomatosis of colorectal cancer.
    Verwaal VJ; Bruin S; Boot H; van Slooten G; van Tinteren H
    Ann Surg Oncol; 2008 Sep; 15(9):2426-32. PubMed ID: 18521686
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Whole-body hyperthermia in combination with platinum-containing drugs in patients with recurrent ovarian cancer.
    Douwes F; BogoviC J; Douwes O; Migeod F; Grote C
    Int J Clin Oncol; 2004 Apr; 9(2):85-91. PubMed ID: 15108039
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Results of a multicenter phase I dose-finding trial of hyperthermic intraperitoneal cisplatin after neoadjuvant chemotherapy and complete cytoreductive surgery and followed by maintenance bevacizumab in initially unresectable ovarian cancer.
    Gouy S; Ferron G; Glehen O; Bayar A; Marchal F; Pomel C; Quenet F; Bereder JM; Le Deley MC; Morice P
    Gynecol Oncol; 2016 Aug; 142(2):237-42. PubMed ID: 27246305
    [TBL] [Abstract][Full Text] [Related]  

  • 89. HIPEC in ovarian cancer: treatment of a new era or is it the end of the pipeline?
    Cascales-Campos P; Gil J; Feliciangeli E; Parrilla P
    Gynecol Oncol; 2015 Nov; 139(2):363-8. PubMed ID: 26091936
    [TBL] [Abstract][Full Text] [Related]  

  • 90. [State of results of HIPEC for epithelial ovarian cancer in the primary treatment or for relapse].
    Classe JM; Frenel JS; Berton D; Gladieff L; Ferron G; Lecuru F; Bourgin C; Narducci F; Loaec C
    Bull Cancer; 2024 Mar; 111(3):261-266. PubMed ID: 36906402
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Evaluation of Cytoreductive Surgery With or Without Hyperthermic Intraperitoneal Chemotherapy for Stage III Epithelial Ovarian Cancer.
    Lei Z; Wang Y; Wang J; Wang K; Tian J; Zhao Y; Chen L; Wang J; Luo J; Jia M; Tang H; He Q; Liao Q; Yang X; Guan T; Wang L; Cui S;
    JAMA Netw Open; 2020 Aug; 3(8):e2013940. PubMed ID: 32840622
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Statement of the AGO Kommission Ovar, AGO Study Group, NOGGO, AGO Austria, Swiss AGO, BGOG, CEEGOG, GEICO, and SFOG regarding the use of hyperthermic intraperitoneal chemotherapy (HIPEC) in epithelial ovarian cancer.
    Harter P; Bogner G; Chiva L; Cibula D; Concin N; Fotopoulou C; Gonzalez-Martin A; Guyon F; Heinzelmann-Schwarz V; Kridelka F; Mahner S; Marmé F; Marth C; Morice P; Novák Z; Papadia A; Ray-Coquard I; Redecha M; Redondo A; Schwameis R; Sehouli J; Undurraga M; Van Gorp T; Vergote I
    Bull Cancer; 2024 Mar; 111(3):277-284. PubMed ID: 36967330
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Translational and pharmacological principles of hyperthermic intraperitoneal chemotherapy for ovarian cancer.
    Vos LMC; Aronson SL; van Driel WJ; Huitema ADR; Schagen van Leeuwen JH; Lok CAR; Sonke GS
    Best Pract Res Clin Obstet Gynaecol; 2022 Jan; 78():86-102. PubMed ID: 34565676
    [TBL] [Abstract][Full Text] [Related]  

  • 94. The role of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the management of recurrent advanced ovarian cancer: a prospective study.
    Spiliotis J; Vaxevanidou A; Sergouniotis F; Lambropoulou E; Datsis A; Christopoulou A
    J BUON; 2011; 16(1):74-9. PubMed ID: 21674853
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for recurrent ovarian carcinoma: analysis of 30-day morbidity and mortality.
    Cripe J; Tseng J; Eskander R; Fader AN; Tanner E; Bristow R
    Ann Surg Oncol; 2015 Feb; 22(2):655-61. PubMed ID: 25155402
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Efficacy of hyperthermic intraperitoneal chemotherapy in patients with epithelial ovarian cancer: a meta-analysis.
    Wu Q; Wu Q; Xu J; Cheng X; Wang X; Lu W; Li X
    Int J Hyperthermia; 2019; 36(1):562-572. PubMed ID: 31137989
    [No Abstract]   [Full Text] [Related]  

  • 97. Peritoneal metastases: challenges for the surgeon.
    Baratti D; Kusamura S; Guaglio M; Deraco M
    Minerva Chir; 2015 Jun; 70(3):195-215. PubMed ID: 25752673
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Consolidation hyperthermic intraperitoneal chemotherapy and maintenance chemotherapy following laparoscopic cytoreductive surgery in the treatment of ovarian carcinoma.
    Rettenmaier MA; Mendivil AA; Abaid LN; Brown Iii JV; Wilcox AM; Goldstein BH
    Int J Hyperthermia; 2015 Feb; 31(1):8-14. PubMed ID: 25559985
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy: a case report.
    Rotruck S; Wilson JT; McGuire J
    AANA J; 2014 Apr; 82(2):140-3. PubMed ID: 24902457
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Current status and future prospects of hyperthermic intraoperative intraperitoneal chemotherapy (HIPEC) clinical trials in ovarian cancer.
    Cowan RA; O'Cearbhaill RE; Zivanovic O; Chi DS
    Int J Hyperthermia; 2017 Aug; 33(5):548-553. PubMed ID: 28092994
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.